Uveitis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Uveitis Treatment Market Analysis
The Uveitis Treatment market will show rapid growth due to the increasing cases of uveitis and the development of novel drugs and treatments and it is expected to grow with a CAGR of 5.8% over the forecasted period.
The market for uveitis treatment is expected to be affected by the COVID - 19 outbreak which is majorly attributed to the lockdown being followed by major countries. Disrupted the supply chain had a direct impact on the market studied as many drugs could not reach the market on time. Uveitis patients are potentially at higher risk of exposure to infections including COVID-19. These above-mentioned elements are expected to burden the revenue trajectory of the global Uveitis Treatment market over the forecast period. However, as respective governing authorities have lifted these enforced lockdowns, the global Uveitis Treatment market is expected to recover accordingly.
The increasing prevalence of optical infections and chronic eye disorders across the globe represents is one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy, and autoimmune and inflammatory disorders. Furthermore, the market is being driven by the growing senior population, which is more sensitive to such disorders. If measures are not taken properly, these diseases can easily spread through human touch (through hands, clothes, or bedding) and by flies that have to meet discharges from an infected person's eyes or nose. In September 2021, a Non-profit group, Prevent Blindness, conducted awareness campaign on various forms of Inflammatory Eye Diseases (IED). In October 2021, ABIONYX Pharma announced the positive pre-clinical results for ER-001 in uveitis treatment and the development of first-class of biomedicines from its bio-HDL for the treatment of ocular pathologies. Thus, the government initiatives for the management of eye pathologies and rising R&D activities for the development of new therapies are some of the significant factors expected to drive the market growth.
Moreover, Trachoma is a disease of the eye caused by infection with the bacterium Chlamydia trachomatis. In March 2020, according to data published by World Health Organization (WHO), around 137 million people live in trachoma endemic areas and are at risk of trachoma blindness. Therefore, the high and increasing prevalence rate of these infectious diseases resulted in the increasing awareness regarding the available alternative treatments for managing uveitis are anticipated to drive the market further. Moreover, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors.
Uveitis Treatment Market Trends
This section covers the major market trends shaping the Uveitis Treatment Market according to our research experts:
Corticosteroids Segment is Expected to Dominate the Market Among Treatment Type Segment During the Forecast Period
Corticosteroids are found dominating the uveitis treatment market as they are first-line therapies for uveitis management and are given systemically or locally, in the form of drops, periocular injection, intravitreal suspension, or intravitreal implant. They are the most preferred option over biologics however researchers are currently exploring biological therapies for the treatment of uveitis. The main advantage of corticosteroids is their ability to quickly and effectively control inflammation early on in the course of uveitis.
In March 2021, according to an article titled 'The global incidence and diagnosis of fungal keratitis' published in Lancet Infectious Diseases, between 1 and 1.4 million fungal eye infections occur in developing countries per year, leaving over 600,000 people blind in one eye. Thus, the increasing prevalence of chronic and viral eye infections requires efficient medication, adoption of corticosteroid medication has increased which is likely in the foreseeable future to maintain the pace of the market for life uveitis market. Some of the available marketed corticosteroids are PRED FORTE (Prednisolone Acetate 1% Ophthalmic Suspension) by AbbVie (Allergan) and Novartis' DUREZOL are used in the management of uveitis. Available ophthalmic suspensions and eye drops in the market were found to produce uveitis mediated quick pain relief, hence this segment will witness steady growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is found dominating the market owing to the rising prevalence of uveitis disease in the United States. A rising research and development activities for uveitis treatment and a strong foothold of major players in the region are driving this region's rapid expansion.
Uveitis is the leading cause of blindness in the United States with a gradual rise in prevalence. In the year 2021, according to a data by 'Eye Health Statistics', Cataracts currently affect more than 24.4 million Americans over age 40, untreated cataract leads to total blindness. Nearly 1 million eye infections occur in the United States each year that are severe enough to require a trip to an eye doctor or a hospital. A large majority of these are related to the inappropriate use of contact lenses. In October 2021, Fresenius Kabi, a German-based company launched an adalimumab injectable biosimilar (Idacio) in Canada. This drug is indicated for adult noninfectious uveitis, and pediatric chronic noninfectious anterior uveitis, and others. Due to better healthcare services and the high number of people suffering from eye infections in this region, the market is expected to hold the largest share in the coming period.
Uveitis Treatment Industry Overview
The uveitis treatment market is highly competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie (Allergan), Inc., and Novartis AG, Bausch Health Inc., AbbVie Inc., Eyegate Pharmaceuticals, Inc., Alimera Science Inc., EyePoint Pharmaceuticals, Santen Pharmaceuticals, and others.
Uveitis Treatment Market Leaders
Bausch Health Inc.
AbbVie Inc.
Eyegate Pharmaceuticals, Inc.
Clearside Biomedical inc.
EyePoint Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Uveitis Treatment Market News
- In October 2021, Bausch + Lomb and Clearside Biomedical announced that the United States Food and Drug Administration (FDA) has approved XIPERE (triamcinolone acetonide). XIPERE is an injectable suspension administered through a suprachoroidal route to treat macular edema associated with uveitis.
- In December 2020, Alimera Sciences Europe Limited has launched ILUVIEN in the Netherlands. ILUVIEN is used in the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU). The strategy behind the launch is geographic expansion, making ILUVIEN available for more physicians and patients in new markets.
Uveitis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Uveitis and its Complications
4.2.2 Rising Expenditure on the Research and Development of New Drugs and Treatments
4.3 Market Restraints
4.3.1 Steep Prices of Medications and Side Effects of The Medication
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Corticosteroids
5.1.2 Antibiotics
5.1.3 Antivirals
5.1.4 Antifungal
5.1.5 Analgesics
5.1.6 Others
5.2 By Disease
5.2.1 Anterior Uveitis
5.2.2 Posterior Uveitis
5.2.3 Intermediate Uveitis
5.2.4 Panuveitis
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bausch Health Inc.
6.1.3 AbbVie Inc.
6.1.4 Eyegate Pharmaceuticals, Inc.
6.1.5 Alimera Science Inc.
6.1.6 EyePoint Pharmaceuticals
6.1.7 Santen Pharmaceuticals
6.1.8 Clearside Biomedical inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Uveitis Treatment Industry Segmentation
As per the scope of this report uveitis treatment refers to various remedies for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of the eye, and sensitivity to light. The Uveitis Treatment Market is segmented By Treatment (Corticosteroids, Antibiotics, Antivirals, Antifungal, Analgesics, and Others), By Disease (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD billion) for the above segments.
| By Treatment | |
| Corticosteroids | |
| Antibiotics | |
| Antivirals | |
| Antifungal | |
| Analgesics | |
| Others |
| By Disease | |
| Anterior Uveitis | |
| Posterior Uveitis | |
| Intermediate Uveitis | |
| Panuveitis |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Uveitis Treatment Market Research FAQs
What is the current Global Uveitis Treatment Market size?
The Global Uveitis Treatment Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Global Uveitis Treatment Market?
Bausch Health Inc. , AbbVie Inc. , Eyegate Pharmaceuticals, Inc., Clearside Biomedical inc. and EyePoint Pharmaceuticals are the major companies operating in the Global Uveitis Treatment Market.
Which is the fastest growing region in Global Uveitis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Uveitis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Uveitis Treatment Market.
What years does this Global Uveitis Treatment Market cover?
The report covers the Global Uveitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Uveitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Uveitis Treatment Industry Report
Statistics for the 2023 Uveitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Uveitis Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
